The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The impact of prior radiation therapy on outcome in a phase 2 trial combining sipuleucel-T (SipT) and ipilimumab (Ipi) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC).
 
Li Zhang
Consulting or Advisory Role - Dendreon; Fortis; Unity Biotechnology
Travel, Accommodations, Expenses - Dendreon; Dendreon; Dendreon
 
Meenal Sinha
No Relationships to Disclose
 
Sumit Kumar Subudhi
Stock and Other Ownership Interests - Apricity Health
Honoraria - Amgen; Apricity Health; AstraZeneca; Bayer; Bristol-Myers Squibb; Dava Oncology; Dendreon; Exelixis; Janssen; Parker Institute for Cancer Immunotherapy; Polaris; Society for Immunotherapy of Cancer
Consulting or Advisory Role - Amgen; Apricity Health; AstraZeneca; Bayer; Bristol-Myers Squibb; Dava Oncology; Dendreon; Janssen; Polaris; Valeant/Dendreon
Research Funding - AstraZeneca; Bristol-Myers Squibb; Janssen
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Compugen; Dava Oncology; Dendreon; Janssen; Parker Institute for Cancer Immunotherapy; Society for Immunotherapy of Cancer
 
Brandon Chen
No Relationships to Disclose
 
Jaqueline Marquez
No Relationships to Disclose
 
Eric Liu
No Relationships to Disclose
 
Kathryn Allaire
No Relationships to Disclose
 
Alexander Cheung
Employment - Genentech (I)
 
Sharon Ng
No Relationships to Disclose
 
Christopher Nguyen
No Relationships to Disclose
 
Terence W. Friedlander
Leadership - Med BioGene
Honoraria - AstraZeneca/MedImmune; EMD Serono; Seattle Genetics/Astellas; Seattle Genetics/Astellas
Consulting or Advisory Role - Abbvie; Abbvie; AstraZeneca; Dava Oncology; Dendreon; EMD Serono; Janssen; Merck; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Incyte (Inst); Janssen; Neon Therapeutics (Inst); Roche/Genentech (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Genentech/Roche; Jounce Therapeutics
 
Rahul Raj Aggarwal
Honoraria - Clovis Oncology
Consulting or Advisory Role - Advanced Accelerator Applications; AstraZeneca; Axiom Biotechnologies; Clovis Oncology; Dendreon
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); BioXCel therapeutics (Inst); Cancer Targeted Technology (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Xynomic Pharma (Inst); Zenith Epigenetics (Inst)
 
Matthew Spitzer
Employment - Surrozen (I)
Leadership - Teiko.bio
Stock and Other Ownership Interests - Surrozen (I); Te Arai BioFarma
Consulting or Advisory Role - Earli; Five Prime Therapeutics; January AI; Ono Pharmaceutical; Teiko.bio
Research Funding - Bristol-Myers Squibb; Pfizer; Roche/Genentech; Valitor
 
James Patrick Allison
Stock and Other Ownership Interests - Achelois Oncology; Achelois Oncology (I); Adaptive Biotechnologies; Adaptive Biotechnologies (I); Apricity Health; Apricity Health (I); BioAtla; BioAtla (I); BioNTech; BioNTech (I); Codiak Biosciences; Codiak Biosciences (I); Constellation Pharmaceuticals; Constellation Pharmaceuticals (I); Dragonfly Therapeutics; Dragonfly Therapeutics (I); Forty Seven; Forty Seven (I); Hummingbird; Hummingbird (I); ImaginAb; ImaginAb (I); Infinity Pharmaceuticals (I); Jounce Therapeutics; Jounce Therapeutics (I); Lava Therapeutics; Lava Therapeutics (I); Lytix Biopharma; Lytix Biopharma (I); Marker Therapeutics; Marker Therapeutics (I); Oncolytics (I); OPTERA; Phenomic AI; Phenomic AI (I); Polaris; Polaris (I)
Patents, Royalties, Other Intellectual Property - Inventor of a patent licensed to Merck; Inventor of a patent owned by Memorial Sloan-Kettering Cancer Center and licensed by Jounce Therapeutics
 
Eric Jay Small
Stock and Other Ownership Interests - Fortis; Harpoon Therapeutics
Honoraria - Janssen; Johnson and Johnson
Consulting or Advisory Role - Beigene; Fortis; Fortis; Janssen Oncology; Teon Therapeutics; Tolero Pharmaceuticals; Ultragenyx Pharmaceuticals
Research Funding - Janssen (Inst)
Travel, Accommodations, Expenses - Janssen
 
Padmanee Sharma
Stock and Other Ownership Interests - Achelois Oncology; Achelois Oncology (I); Apricity Health; Apricity Health (I); BioAtla; BioAtla (I); BioNTech; BioNTech (I); Codiak Biosciences; Codiak Biosciences (I); Constellation Pharmaceuticals; Constellation Pharmaceuticals (I); Dragonfly Therapeutics; Dragonfly Therapeutics (I); Forty Seven; Forty Seven (I); Glympse Bio; Hummingbird; Hummingbird (I); ImaginAb; ImaginAb (I); Infinity Pharmaceuticals; Jounce Therapeutics; Jounce Therapeutics (I); Lava Therapeutics; Lava Therapeutics (I); Lytix Biopharma; Lytix Biopharma (I); Marker Therapeutics; Marker Therapeutics (I); Oncolytics; Polaris; Polaris (I)
Consulting or Advisory Role - Achelois Oncology; Achelois Oncology (I); Apricity Health; Apricity Health (I); BioAtla; BioAtla (I); Codiak Biosciences; Codiak Biosciences (I); Constellation Pharmaceuticals; Dragonfly Therapeutics; Dragonfly Therapeutics (I); Forty Seven; Forty Seven (I); Glympse Bio; Hummingbird; Hummingbird (I); ImaginAb; ImaginAb (I); Infinity Pharmaceuticals; Jounce Therapeutics; Jounce Therapeutics (I); Lava Therapeutics; Lava Therapeutics (I); Lytix Biopharma; Lytix Biopharma (I); Marker Therapeutics; Marker Therapeutics (I); Oncolytics; Polaris; Polaris (I)
Patents, Royalties, Other Intellectual Property - Own patent licensed to Jounce; Own patents licensed to BMS, Jounce & Merck (I)
 
Lawrence Fong
Stock and Other Ownership Interests - Alector; Alector; Atreca; BioAtla; Bolt Biotherapeutics; Nutcracker Therapeutics, Inc.; RAPT Therapeutics; TeneoBio; TeneoBio
Consulting or Advisory Role - Alector; AstraZeneca; Atreca; BioAtla; Bolt Biotherapeutics; Bristol-Myers Squibb; Dendreon; EMD Serono; Janssen Oncology; Nutcracker Therapeutics, Inc.; RAPT Therapeutics; TeneoBio
Research Funding - Abbvie (Inst); Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Janssen Oncology (Inst); Merck (Inst); Roche/Genentech (Inst)